{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T08:18:17Z","timestamp":1788164297935,"version":"build-2803163510"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["113-3437-001-111"],"award-info":[{"award-number":["113-3437-001-111"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["112-5812-004-400"],"award-info":[{"award-number":["112-5812-004-400"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["114-2320-B-038 -016"],"award-info":[{"award-number":["114-2320-B-038 -016"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC112-2320-B-038-026-MY3"],"award-info":[{"award-number":["NSTC112-2320-B-038-026-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Personalized neoantigen cancer vaccine is\u00a0a promising strategy for precision immunotherapy by targeting patient-specific and mutation-derived tumor antigens. Early clinical studies have demonstrated the feasibility, safety, and immunogenicity of these vaccines across multiple solid tumors, with encouraging outcomes particularly when combined with immune checkpoint blockade. However, broader clinical translation remains limited by sequential bottlenecks across the vaccine development pipeline, including false-positive neoantigen selection, \u00a0imperfect modeling of antigen processing and HLA presentation, limited prediction of T-cell receptor recognition, and challenges in formulation, delivery, and manufacturing. Artificial intelligence and advanced computational workflows are increasingly integrated into this pipeline to improve candidate prioritization and support more reproducible decision-making. In this review, we summarize clinical progress and key translational barriers in personalized neoantigen vaccination, and discuss how AI-enabled approaches may contribute across four major stages: multi-omics integration for neoantigen discovery, processing-aware HLA presentation prediction, structure-aware and TCR-informed immunogenicity modeling, and data-driven formulation optimization, particularly for lipid nanoparticle-based delivery systems. These approaches are able to\u00a0help narrow biological and chemical search spaces, improve prioritization, and provide mechanistic insights into antigen presentation and immune recognition rather than replacing experimental validation. This articlefurther addresses\u00a0future implementation challenges, including dataset diversity, model interpretability, prospective benchmarking, manufacturing traceability, and evolving regulatory frameworks for individualized mRNA cancer immunotherapies. Integrating computational innovation with rigorous immunological validation, scalable manufacturing, and regulatory oversight will be essential for advancing personalized neoantigen vaccines toward broader clinical implementation.<\/jats:p>","DOI":"10.1186\/s12929-026-01286-3","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T07:35:52Z","timestamp":1788161752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Artificial intelligence for translational personalized neoantigen cancer vaccine development"],"prefix":"10.1186","volume":"33","author":[{"given":"Chun-Yu","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Chao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Jiun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Nan","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Mai","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Hsuan","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Po","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Hsiang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Chen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shisong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.","family":"Fairfax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chiao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"issue":"4","key":"1286_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215\u201329.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1286_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","volume":"21","author":"F Lang","year":"2022","unstructured":"Lang F, Schrors B, Lower M, Tureci O, Sahin U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discov. 2022;21(4):261\u201382.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"1286_CR3","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.annonc.2020.05.008","volume":"31","author":"L De Mattos-Arruda","year":"2020","unstructured":"De Mattos-Arruda L, Vazquez M, Finotello F, Lepore R, Porta E, Hundal J, et al. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(8):978\u201390.","journal-title":"Ann Oncol"},{"issue":"5","key":"1286_CR4","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41587-026-03018-2","volume":"44","author":"PA Ott","year":"2026","unstructured":"Ott PA. The promises and challenges of neoantigen cancer vaccines. Nat Biotechnol. 2026;44(5):740\u201351.","journal-title":"Nat Biotechnol"},{"key":"1286_CR5","doi-asserted-by":"crossref","unstructured":"Ho SY, Chang CM, Liao HN, Chou WH, Guo CL, Yen Y, Nakamura Y, Chang WC. Current Trends in Neoantigen-Based Cancer Vaccines. Pharmaceuticals 2023;16(3):392.","DOI":"10.3390\/ph16030392"},{"issue":"12","key":"1286_CR6","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","volume":"22","author":"N Pishesha","year":"2022","unstructured":"Pishesha N, Harmand TJ, Ploegh HL. A guide to antigen processing and presentation. Nat Rev Immunol. 2022;22(12):751\u201364.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"1286_CR7","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","volume":"20","author":"E Kon","year":"2023","unstructured":"Kon E, Ad-El N, Hazan-Halevy I, Stotsky-Oterin L, Peer D. Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects. Nat Rev Clin Oncol. 2023;20(11):739\u201354.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1286_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s42256-023-00634-4","volume":"5","author":"X Peng","year":"2023","unstructured":"Peng X, Lei Y, Feng P, Jia L, Ma J, Zhao D, et al. Characterizing the interaction conformation between T-cell receptors and epitopes with deep learning. Nat Mach Intell. 2023;5(4):395\u2013407.","journal-title":"Nat Mach Intell"},{"issue":"8","key":"1286_CR9","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","volume":"43","author":"F Huber","year":"2025","unstructured":"Huber F, Arnaud M, Stevenson BJ, Michaux J, Benedetti F, Thevenet J, et al. A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy. Nat Biotechnol. 2024. https:\/\/doi.org\/10.1038\/s41587-024-02420-y.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1286_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023;8(1):9.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1286_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/cancers18010144","volume":"18","author":"AC Wu","year":"2025","unstructured":"Wu AC, Nakamura Y, Kiyotani K. Advances in neoantigen-based cancer vaccines. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers18010144.","journal-title":"Cancers (Basel)"},{"issue":"7662","key":"1286_CR12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, L\u00f6wer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222\u20136.","journal-title":"Nature"},{"issue":"4","key":"1286_CR13","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","volume":"30","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan M, Gane EJ, Marron TU, Perales-Linares R, Yan J, Cooch N, et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. Nat Med. 2024;30(4):1044\u201353.","journal-title":"Nat Med"},{"issue":"2","key":"1286_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell. 2020;183(2):347-62.e24.","journal-title":"Cell"},{"issue":"11","key":"1286_CR15","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/1078-0432.CCR-23-3940","volume":"30","author":"AM D'Alise","year":"2024","unstructured":"D\u2019Alise AM, Leoni G, Cotugno G, Siani L, Vitale R, Ruzza V, et al. Phase I trial of viral vector-based personalized vaccination elicits robust neoantigen-specific antitumor T-cell responses. Clin Cancer Res. 2024;30(11):2412\u201323.","journal-title":"Clin Cancer Res"},{"issue":"10427","key":"1286_CR16","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632\u201344.","journal-title":"Lancet"},{"issue":"1","key":"1286_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","volume":"6","author":"Z Ding","year":"2021","unstructured":"Ding Z, Li Q, Zhang R, Xie L, Shu Y, Gao S, et al. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct Target Ther. 2021;6(1):26.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"1286_CR18","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu Z, Leet DE, Allesoe RL, Oliveira G, Li S, Luoma AM, et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021;27(3):515\u201325.","journal-title":"Nat Med"},{"issue":"7963","key":"1286_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144\u201350.","journal-title":"Nature"},{"issue":"8054","key":"1286_CR20","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","volume":"639","author":"DA Braun","year":"2025","unstructured":"Braun DA, Moranzoni G, Chea V, McGregor BA, Blass E, Tu CR, et al. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature. 2025;639(8054):474\u201382.","journal-title":"Nature"},{"issue":"9","key":"1286_CR21","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","volume":"40","author":"MM Awad","year":"2022","unstructured":"Awad MM, Govindan R, Balogh KN, Spigel DR, Garon EB, Bushway ME, et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell. 2022;40(9):1010-26.e11.","journal-title":"Cancer Cell"},{"issue":"1","key":"1286_CR22","doi-asserted-by":"publisher","first-page":"2023255","DOI":"10.1080\/2162402X.2021.2023255","volume":"11","author":"SK Mork","year":"2022","unstructured":"Mork SK, Kadivar M, Bol KF, Draghi A, Westergaard MCW, Skadborg SK, et al. Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF(R)09b, in patients with metastatic melanoma. Oncoimmunology. 2022;11(1):2023255.","journal-title":"Oncoimmunology"},{"key":"1286_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/or.2025.1541326","volume":"19","author":"P Singh","year":"2025","unstructured":"Singh P, Khatib MN, R R, Kaur M, Srivastava M, Barwal A, et al. Advancements and challenges in personalized neoantigen-based cancer vaccines. Oncol Rev. 2025;19:1541326.","journal-title":"Oncol Rev"},{"key":"1286_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2021.100052","volume":"12","author":"G Fotakis","year":"2021","unstructured":"Fotakis G, Trajanoski Z, Rieder D. Computational cancer neoantigen prediction: current status and recent advances. Immunooncol Technol. 2021;12:100052.","journal-title":"Immunooncol Technol"},{"issue":"Pt A","key":"1286_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113147","volume":"142","author":"Y Ren","year":"2024","unstructured":"Ren Y, Yue Y, Li X, Weng S, Xu H, Liu L, et al. Proteogenomics offers a novel avenue in neoantigen identification for cancer immunotherapy. Int Immunopharmacol. 2024;142(Pt A):113147.","journal-title":"Int Immunopharmacol"},{"issue":"10499","key":"1286_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0140-6736(25)00553-7","volume":"406","author":"O Pail","year":"2025","unstructured":"Pail O, Lin MJ, Anagnostou T, Brown BD, Brody JD. Cancer vaccines and the future of immunotherapy. Lancet. 2025;406(10499):189\u2013202.","journal-title":"Lancet"},{"issue":"7662","key":"1286_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217\u201321.","journal-title":"Nature"},{"issue":"3","key":"1286_CR28","doi-asserted-by":"publisher","first-page":"bbac141","DOI":"10.1093\/bib\/bbac141","volume":"23","author":"PR Buckley","year":"2022","unstructured":"Buckley PR, Lee CH, Ma R, Woodhouse I, Woo J, Tsvetkov VO, et al. Evaluating performance of existing computational models in predicting CD8+ T cell pathogenic epitopes and cancer neoantigens. Briefings Bioinf. 2022;23(3):bbac141.","journal-title":"Brief Bioinform."},{"issue":"6","key":"1286_CR29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.trecan.2026.02.003","volume":"12","author":"IE Shapiro","year":"2026","unstructured":"Shapiro IE, Bassani-Sternberg M. From prediction to precision: how immunopeptidomics advances neoantigen discovery. Trends Cancer. 2026. https:\/\/doi.org\/10.1016\/j.trecan.2026.02.003.","journal-title":"Trends Cancer"},{"issue":"1","key":"1286_CR30","doi-asserted-by":"publisher","first-page":"e013271","DOI":"10.1136\/jitc-2025-013271","volume":"14","author":"BKQ Zaghla","year":"2026","unstructured":"Zaghla BKQ, Safyurek Z, Groger D, Mecklenbrauker S, Lingstadt NS, Popp O, et al. Systematic evaluation of neoepitope predictions challenges clinically observed T-cell responses and their impact on immune evasion. J Immunother Cancer. 2026. https:\/\/doi.org\/10.1136\/jitc-2025-013271.","journal-title":"J Immunother Cancer"},{"key":"1286_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.833017","volume":"13","author":"MJW Sim","year":"2022","unstructured":"Sim MJW, Sun PD. T cell recognition of tumor neoantigens and insights into T cell immunotherapy. Front Immunol. 2022;13:833017.","journal-title":"Front Immunol"},{"key":"1286_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303304","volume":"14","author":"RA Mariuzza","year":"2023","unstructured":"Mariuzza RA, Wu D, Pierce BG. Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity. Front Immunol. 2023;14:1303304.","journal-title":"Front Immunol"},{"key":"1286_CR33","doi-asserted-by":"publisher","first-page":"e82813","DOI":"10.7554\/eLife.82813","volume":"12","author":"P Bradley","year":"2023","unstructured":"Bradley P. Structure-based prediction of T cell receptor:peptide-MHC interactions. Elife. 2023. https:\/\/doi.org\/10.7554\/eLife.82813.","journal-title":"Elife"},{"key":"1286_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02047","volume":"10","author":"TP Riley","year":"2019","unstructured":"Riley TP, Keller GLJ, Smith AR, Davancaze LM, Arbuiso AG, Devlin JR, et al. Structure based prediction of neoantigen immunogenicity. Front Immunol. 2019;10:2047.","journal-title":"Front Immunol"},{"issue":"2","key":"1286_CR35","doi-asserted-by":"publisher","first-page":"bbag123","DOI":"10.1093\/bib\/bbag123","volume":"27","author":"Y Deng","year":"2026","unstructured":"Deng Y, Que J, Xue G, Cai Y, Yang W, Wang Y, et al. AI-driven computational methods and benchmarking for T-cell antigen identification. Brief Bioinform. 2026. https:\/\/doi.org\/10.1093\/bib\/bbag123.","journal-title":"Brief Bioinform"},{"key":"1286_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1128326","volume":"14","author":"L Deng","year":"2023","unstructured":"Deng L, Ly C, Abdollahi S, Zhao Y, Prinz I, Bonn S. Performance comparison of TCR-pMHC prediction tools reveals a strong data dependency. Front Immunol. 2023;14:1128326.","journal-title":"Front Immunol"},{"issue":"1","key":"1286_CR37","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41592-025-02910-0","volume":"23","author":"Y Lu","year":"2026","unstructured":"Lu Y, Wang Y, Xu M, Xie B, Yang Y, Xu H, et al. Assessment of computational methods in predicting TCR-epitope binding recognition. Nat Methods. 2026;23(1):248\u201359.","journal-title":"Nat Methods"},{"issue":"13","key":"1286_CR38","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1158\/0008-5472.CAN-24-2553","volume":"85","author":"J Zeng","year":"2025","unstructured":"Zeng J, Lin Z, Zhang X, Zheng T, Xu H, Liu T. Leveraging artificial intelligence for neoantigen prediction. Cancer Res. 2025;85(13):2376\u201387.","journal-title":"Cancer Res"},{"issue":"6","key":"1286_CR39","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","volume":"40","author":"AJ Barbier","year":"2022","unstructured":"Barbier AJ, Jiang AY, Zhang P, Wooster R, Anderson DG. The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol. 2022;40(6):840\u201354.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1286_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-025-02645-6","volume":"22","author":"KY Leong","year":"2025","unstructured":"Leong KY, Tham SK, Poh CL. Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications. Virol J. 2025;22(1):71.","journal-title":"Virol J"},{"key":"1286_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1288105","volume":"14","author":"TK Atkins","year":"2023","unstructured":"Atkins TK, Solanki A, Vasmatzis G, Cornette J, Riedel M. Evaluating NetMHCpan performance on non-European HLA alleles not present in training data. Front Immunol. 2023;14:1288105.","journal-title":"Front Immunol"},{"issue":"8","key":"1286_CR42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2405106122","volume":"122","author":"E Glynn","year":"2025","unstructured":"Glynn E, Ghersi D, Singh M. Toward equitable major histocompatibility complex binding predictions. Proc Natl Acad Sci U S A. 2025;122(8):e2405106122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1286_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1054231","volume":"12","author":"Y Cai","year":"2022","unstructured":"Cai Y, Chen R, Gao S, Li W, Liu Y, Su G, et al. Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy. Front Oncol. 2022;12:1054231.","journal-title":"Front Oncol"},{"key":"1286_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1394003","volume":"15","author":"A Bulashevska","year":"2024","unstructured":"Bulashevska A, Nacsa Z, Lang F, Braun M, Machyna M, Diken M, et al. Artificial intelligence and neoantigens: paving the path for precision cancer immunotherapy. Front Immunol. 2024;15:1394003.","journal-title":"Front Immunol"},{"issue":"Suppl 5","key":"1286_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12920-020-0683-4","volume":"13","author":"Y Li","year":"2020","unstructured":"Li Y, Wang G, Tan X, Ouyang J, Zhang M, Song X, et al. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection. BMC Med Genomics. 2020;13(Suppl 5):52.","journal-title":"BMC Med Genomics"},{"issue":"5","key":"1286_CR46","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3390\/genes13050783","volume":"13","author":"C Liu","year":"2022","unstructured":"Liu C, Zhang Y, Jian X, Tan X, Lu M, Ouyang J, et al. ProGeo-Neo v2.0: a one-stop software for neoantigen prediction and filtering based on the proteogenomics strategy. Genes. 2022. https:\/\/doi.org\/10.3390\/genes13050783.","journal-title":"Genes"},{"issue":"2","key":"1286_CR47","doi-asserted-by":"publisher","first-page":"bbae024","DOI":"10.1093\/bib\/bbae024","volume":"25","author":"GS Chuwdhury","year":"2024","unstructured":"Chuwdhury GS, Guo Y, Chiang CL, Lam KO, Kam NW, Liu Z, et al. ImmuneMirror: a machine learning-based integrative pipeline and web server for neoantigen prediction. Brief Bioinform. 2024. https:\/\/doi.org\/10.1093\/bib\/bbae024.","journal-title":"Brief Bioinform"},{"issue":"19","key":"1286_CR48","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1093\/bioinformatics\/btx377","volume":"33","author":"E Tappeiner","year":"2017","unstructured":"Tappeiner E, Finotello F, Charoentong P, Mayer C, Rieder D, Trajanoski Z. TIminer: NGS data mining pipeline for cancer immunology and immunotherapy. Bioinformatics. 2017;33(19):3140\u20131.","journal-title":"Bioinformatics"},{"issue":"3","key":"1286_CR49","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1158\/2326-6066.CIR-19-0401","volume":"8","author":"J Hundal","year":"2020","unstructured":"Hundal J, Kiwala S, McMichael J, Miller CA, Xia H, Wollam AT, et al. pVACtools: a computational toolkit to identify and visualize cancer neoantigens. Cancer Immunol Res. 2020;8(3):409\u201320.","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"1286_CR50","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","volume":"19","author":"CC Smith","year":"2019","unstructured":"Smith CC, Selitsky SR, Chai S, Armistead PM, Vincent BG, Serody JS. Alternative tumour-specific antigens. Nat Rev Cancer. 2019;19(8):465\u201378.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"1286_CR51","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMcibr1814237","volume":"380","author":"JE Slansky","year":"2019","unstructured":"Slansky JE, Spellman PT. Alternative splicing in tumors - a path to immunogenicity? N Engl J Med. 2019;380(9):877\u201380.","journal-title":"N Engl J Med"},{"issue":"4","key":"1286_CR52","doi-asserted-by":"publisher","first-page":"eabj3671","DOI":"10.1126\/sciadv.abj3671","volume":"8","author":"P Bonaventura","year":"2022","unstructured":"Bonaventura P, Alcazer V, Mutez V, Tonon L, Martin J, Chuvin N, et al. Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy. Sci Adv. 2022;8(4):eabj3671.","journal-title":"Sci Adv"},{"issue":"9","key":"1286_CR53","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol. 2017;199(9):3360\u20138.","journal-title":"J Immunol"},{"issue":"1","key":"1286_CR54","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cels.2020.06.010","volume":"11","author":"TJ O\u2019Donnell","year":"2020","unstructured":"O\u2019Donnell TJ, Rubinsteyn A, Laserson U. MHCflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing. Cell Syst. 2020;11(1):42\u20138.","journal-title":"Cell Syst"},{"issue":"1","key":"1286_CR55","doi-asserted-by":"publisher","first-page":"bbae595","DOI":"10.1093\/bib\/bbae595","volume":"26","author":"Y Chang","year":"2024","unstructured":"Chang Y, Wu L. CapHLA: a comprehensive tool to predict peptide presentation and binding to HLA class I and class II. Brief Bioinform. 2024;26(1):bbae595.","journal-title":"Brief Bioinform"},{"issue":"47","key":"1286_CR56","doi-asserted-by":"publisher","first-page":"eadj6367","DOI":"10.1126\/sciadv.adj6367","volume":"9","author":"JB Nilsson","year":"2023","unstructured":"Nilsson JB, Kaabinejadian S, Yari H, Kester MGD, van Balen P, Hildebrand WH, et al. Accurate prediction of HLA class II antigen presentation across all loci using tailored data acquisition and refined machine learning. Sci Adv. 2023;9(47):eadj6367.","journal-title":"Sci Adv"},{"issue":"2","key":"1286_CR57","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s42256-024-00971-y","volume":"7","author":"J Wohlwend","year":"2025","unstructured":"Wohlwend J, Nathan A, Shalon N, Crain CR, Tano-Menka R, Goldberg B, et al. Deep learning enhances the prediction of HLA class I-presented CD8(+) T cell epitopes in foreign pathogens. Nat Mach Intell. 2025;7(2):232\u201343.","journal-title":"Nat Mach Intell"},{"issue":"6","key":"1286_CR58","doi-asserted-by":"publisher","first-page":"bbab160","DOI":"10.1093\/bib\/bbab160","volume":"22","author":"G Li","year":"2021","unstructured":"Li G, Iyer B, Prasath VBS, Ni Y, Salomonis N. DeepImmuno: deep learning-empowered prediction and generation of immunogenic peptides for T-cell immunity. Brief Bioinform. 2021;22(6):bbab160.","journal-title":"Brief Bioinform"},{"issue":"W1","key":"1286_CR59","doi-asserted-by":"publisher","first-page":"W134","DOI":"10.1093\/nar\/gkad275","volume":"51","author":"JY Kim","year":"2023","unstructured":"Kim JY, Bang H, Noh SJ, Choi JK. DeepNeo: a webserver for predicting immunogenic neoantigens. Nucleic Acids Res. 2023;51(W1):W134\u201340.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"1286_CR60","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41590-023-01543-9","volume":"24","author":"SE Brightman","year":"2023","unstructured":"Brightman SE, Becker A, Thota RR, Naradikian MS, Chihab L, Zavala KS, et al. Neoantigen-specific stem cell memory-like CD4(+) T cells mediate CD8(+) T cell-dependent immunotherapy of MHC class II-negative solid tumors. Nat Immunol. 2023;24(8):1345\u201357.","journal-title":"Nat Immunol"},{"issue":"11","key":"1286_CR61","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41587-019-0280-2","volume":"37","author":"B Chen","year":"2019","unstructured":"Chen B, Khodadoust MS, Olsson N, Wagar LE, Fast E, Liu CL, et al. Predicting HLA class II antigen presentation through integrated deep learning. Nat Biotechnol. 2019;37(11):1332\u201343.","journal-title":"Nat Biotechnol"},{"issue":"47","key":"1286_CR62","doi-asserted-by":"publisher","first-page":"eadq6150","DOI":"10.1126\/sciadv.adq6150","volume":"10","author":"D Wu","year":"2024","unstructured":"Wu D, Yin R, Chen G, Ribeiro-Filho HV, Cheung M, Robbins PF, et al. Structural characterization and AlphaFold modeling of human T cell receptor recognition of NRAS cancer neoantigens. Sci Adv. 2024;10(47):bbab6150.","journal-title":"Sci Adv"},{"issue":"8016","key":"1286_CR63","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630(8016):493\u2013500.","journal-title":"Nature"},{"issue":"1","key":"1286_CR64","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/s42003-021-02610-3","volume":"4","author":"A Montemurro","year":"2021","unstructured":"Montemurro A, Schuster V, Povlsen HR, Bentzen AK, Jurtz V, Chronister WD, et al. NetTCR-2.0 enables accurate prediction of TCR-peptide binding by using paired TCR\u03b1 and \u03b2 sequence data. Commun Biol. 2021;4(1):1060.","journal-title":"Commun Biol."},{"issue":"1","key":"1286_CR65","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/s41467-021-21879-w","volume":"12","author":"JW Sidhom","year":"2021","unstructured":"Sidhom JW, Larman HB, Pardoll DM, Baras AS. DeepTCR is a deep learning framework for revealing sequence concepts within T-cell repertoires. Nat Commun. 2021;12(1):1605.","journal-title":"Nat Commun"},{"issue":"22","key":"1286_CR66","doi-asserted-by":"publisher","first-page":"9881","DOI":"10.1039\/D4SC08141B","volume":"16","author":"J Ge","year":"2025","unstructured":"Ge J, Wang J, Ye Q, Pan L, Kang Y, Shen C, et al. TRAP: a contrastive learning-enhanced framework for robust TCR-pMHC binding prediction with improved generalizability. Chem Sci. 2025;16(22):9881\u201394.","journal-title":"Chem Sci"},{"issue":"5","key":"1286_CR67","doi-asserted-by":"publisher","first-page":"bbaf496","DOI":"10.1093\/bib\/bbaf496","volume":"26","author":"X Li","year":"2025","unstructured":"Li X, Sun C, Huang W, Wang Y, Ma B. SageTCR: a structure-based model integrating residue- and atom-level representations for enhanced TCR-pMHC binding prediction. Brief Bioinform. 2025;26(5):bbaf496.","journal-title":"Brief Bioinform"},{"issue":"4","key":"1286_CR68","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s42256-025-01002-0","volume":"7","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Yu J, Su Y, Shu Y, Ma E, Wang J, et al. A unified deep framework for peptide\u2013major histocompatibility complex\u2013T cell receptor binding prediction. Nat Mach Intell. 2025. https:\/\/doi.org\/10.1038\/s42256-025-01002-0.","journal-title":"Nat Mach Intell"},{"issue":"12","key":"1286_CR69","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078\u201394.","journal-title":"Nat Rev Mater"},{"issue":"11","key":"1286_CR70","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2307798120","volume":"121","author":"J Witten","year":"2024","unstructured":"Witten J, Hu Y, Langer R, Anderson DG. Recent advances in nanoparticulate RNA delivery systems. Proc Natl Acad Sci U S A. 2024;121(11):e2307798120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1286_CR71","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1038\/s41467-024-50619-z","volume":"15","author":"Y Xu","year":"2024","unstructured":"Xu Y, Ma S, Cui H, Chen J, Xu S, Gong F, et al. AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery. Nat Commun. 2024;15(1):6305.","journal-title":"Nat Commun"},{"issue":"1","key":"1286_CR72","doi-asserted-by":"publisher","first-page":"10804","DOI":"10.1038\/s41467-024-55072-6","volume":"15","author":"W Wang","year":"2024","unstructured":"Wang W, Chen K, Jiang T, Wu Y, Wu Z, Ying H, et al. Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery. Nat Commun. 2024;15(1):10804.","journal-title":"Nat Commun"},{"issue":"11","key":"1286_CR73","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1038\/s41587-024-02490-y","volume":"43","author":"J Witten","year":"2025","unstructured":"Witten J, Raji I, Manan RS, Beyer E, Bartlett S, Tang Y, et al. Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy. Nat Biotechnol. 2025;43(11):1790\u20139.","journal-title":"Nat Biotechnol"},{"key":"1286_CR74","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.partic.2023.11.014","volume":"90","author":"Y Yuan","year":"2024","unstructured":"Yuan Y, Wu Y, Cheng J, Yang K, Xia Y, Wu H, et al. Applications of artificial intelligence to lipid nanoparticle delivery. Particuology. 2024;90:88\u201397.","journal-title":"Particuology"},{"issue":"11","key":"1286_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2024.100996","volume":"14","author":"R Maharjan","year":"2024","unstructured":"Maharjan R, Kim KH, Lee K, Han HK, Jeong SH. Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost\/Bayesian method and ensemble model approaches. J Pharm Anal. 2024;14(11):100996.","journal-title":"J Pharm Anal"},{"issue":"11","key":"1286_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1006457","volume":"14","author":"W Zhao","year":"2018","unstructured":"Zhao W, Sher X. Systematically benchmarking peptide-MHC binding predictors: from synthetic to naturally processed epitopes. PLoS Comput Biol. 2018;14(11):e1006457.","journal-title":"PLoS Comput Biol"},{"key":"1286_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1094236","volume":"14","author":"G Nibeyro","year":"2023","unstructured":"Nibeyro G, Baronetto V, Folco JI, Pastore P, Girotti MR, Prato L, et al. Unraveling tumor specific neoantigen immunogenicity prediction: a comprehensive analysis. Front Immunol. 2023;14:1094236.","journal-title":"Front Immunol"},{"issue":"4","key":"1286_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2023.100506","volume":"22","author":"RM Pyke","year":"2023","unstructured":"Pyke RM, Mellacheruvu D, Dea S, Abbott C, Zhang SV, Phillips NA, et al. Precision neoantigen discovery using large-scale immunopeptidomes and composite modeling of MHC peptide presentation. Mol Cell Proteomics. 2023;22(4):100506.","journal-title":"Mol Cell Proteomics"},{"issue":"38","key":"1286_CR79","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado6491","volume":"10","author":"S Tokita","year":"2024","unstructured":"Tokita S, Fusagawa M, Matsumoto S, Mariya T, Umemoto M, Hirohashi Y, et al. Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes. Sci Adv. 2024;10(38):eado6491.","journal-title":"Sci Adv"},{"key":"1286_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1293706","volume":"15","author":"Y Yang","year":"2024","unstructured":"Yang Y, Wei Z, Cia G, Song X, Pucci F, Rooman M, et al. MHCII-peptide presentation: an assessment of the state-of-the-art prediction methods. Front Immunol. 2024;15:1293706.","journal-title":"Front Immunol"},{"issue":"7","key":"1286_CR81","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.4049\/jimmunol.2100700","volume":"208","author":"ES Borden","year":"2022","unstructured":"Borden ES, Ghafoor S, Buetow KH, LaFleur BJ, Wilson MA, Hastings KT. NeoScore integrates characteristics of the neoantigen:MHC class I interaction and expression to accurately prioritize immunogenic neoantigens. J Immunol. 2022;208(7):1813\u201327.","journal-title":"J Immunol"},{"key":"1286_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2020.103655","volume":"113","author":"AF Markus","year":"2021","unstructured":"Markus AF, Kors JA, Rijnbeek PR. The role of explainability in creating trustworthy artificial intelligence for health care: a comprehensive survey of the terminology, design choices, and evaluation strategies. J Biomed Inform. 2021;113:103655.","journal-title":"J Biomed Inform"},{"key":"1286_CR83","unstructured":"Medicines and Healthcare products Regulatory Agency. Draft guidance on individualised mRNA cancer immunotherapies 2025 Available from: https:\/\/www.gov.uk\/government\/consultations\/draft-guidance-on-individualised-mrna-cancer-immunotherapies."},{"issue":"7_Supplement","key":"1286_CR84","doi-asserted-by":"publisher","first-page":"CT141","DOI":"10.1158\/1538-7445.AM2024-CT141","volume":"84","author":"JE Bauman","year":"2024","unstructured":"Bauman JE, Julian RA, Geiger JL, Mehnert JM, Clarke JM, Patel MR, et al. Abstract CT141: mRNA-4157 (V940) individualized neoantigen therapy (INT) + pembrolizumab (pembro) in advanced unresectable HPV- head & neck carcinoma (HNSCC): clinical & translational analysis. Cancer Res. 2024;84(7_Supplement):CT141.","journal-title":"Cancer Res"},{"issue":"8056","key":"1286_CR85","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, et al. RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer. Nature. 2025;639(8056):1042\u201351.","journal-title":"Nature"},{"issue":"7738","key":"1286_CR86","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234\u20139.","journal-title":"Nature"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-026-01286-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-026-01286-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-026-01286-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T08:03:04Z","timestamp":1788163384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12929-026-01286-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1286"],"URL":"https:\/\/doi.org\/10.1186\/s12929-026-01286-3","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors agree to publish this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"87"}}